OrphoMed: FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that the U.S.read more
Read full article »
OrphoMed is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders.
Read more